Outcomes from 14 and 15 May 2019 Taskforce meeting

On the 14 and 15 of May 2019, the Medicare Benefits Schedule (MBS) Review Taskforce (the Taskforce) held its 39th meeting. The following is a summary of the outcomes arising from the meeting.

Page last updated: 12 November 2019

MBS Review Taskforce meeting outcomes 14 and 15 May 2019 (PDF 99 KB)

MBS Review Update

The Department gave an update on the progress of the review.

Principles and Rules Committee

The Taskforce noted the Principles and Rules Committee’s (PARC) update.

Paediatric Surgery Advisory Group

The Paediatric Surgery Advisory Group Report was endorsed for Consultation.

Vascular Clinical Committee

The Taskforce noted the update from the Vascular Clinical Committee.

General Surgery Clinical Committee

The Taskforce endorsed the General Surgery Report for Government.

Otolaryngology Head and Neck Surgery Clinical Committee

The Taskforce endorsed the Otolaryngology Head and Neck Surgery Clinical Committee Report for Consultation.

Plastics and Reconstructive Surgery Committee

The Plastics and Reconstructive Surgery Report was Endorsed for Government.

Injections Working Group

The Taskforce agreed to the recommendation to reintroduce item 50124 for unguided joint injection with an amended Explanatory Note detailing appropriate indications for image guidance.

Wound Management Working Group

The Taskforce endorsed the Wounds Management Working Group Report to be released for Consultation as an options paper.

Oral and Maxillofacial Services – Category 4

The Taskforce noted the update on the process for Oral and Maxillofacial Services – Category 4.

Cleft Dental Services Working Group– Category 7

The Taskforce endorsed Cleft Dental Services – Category 7 for consultation.

Colorectal Surgery Committee

The Taskforce provisionally endorsed the Colorectal Surgery Committee report for Government, pending consideration at the August Taskforce meeting of prolapse repair items and options for pelvic exenteration items.

Consumer Panel

The Consumer Panel Report was endorsed for consultation.

Diagnostic Medicine Clinical Committee

The Taskforce noted the update to the Diagnostic Medicine Clinical Committee.